Article
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Cancer research - 1 Nov 2010
Yamamoto Chizuko, Basaki Yuji, Kawahara Akihiko, Nakashima Kazutaka, Kage Masayoshi, Izumi Hiroto, Kohno Kimitoshi, Uramoto Hidetaka, Yasumoto Kosei, Kuwano Michihiko, Ono Mayumi
Abstract excerpt
Gefitinib (Iressa) and erlotinib (Tarceva), which target the epidermal growth factor receptor (EGFR), are approved for treatment of patients with advanced non-small cell lung cancer (NSCLC). Patients whose tumors harbor mutations in the EGFR gene, including delE746-A750 in exon 19 and L858R in exon 21, may benefit in particular from gefitinib treatment. However, acquired resistance to gefitinib has been a serious...
Topics
- Blotting, Western
- Carcinoma, Non-Small-Cell Lung
- Cell Nucleus
- Cell Proliferation
- Drug Resistance, Neoplasm
- Early Growth Response Protein 1
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib